leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...124125126127128129130131132133134...235236»
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Peritoneal cytology as an indicator of peritoneal metastases in colorectal cancer. (Pubmed Central) -  Aug 25, 2021   
    Systematic drug-level testing in PT under PY/SA treatment deserves to be considered. Peritoneal cytology identified patients with mucinous histology and a large extent of disease but was consistently negative in patients who had a small extent of disease compatible with a favorable response to treatment.
  • ||||||||||  irinotecan / Generic mfg.
    Clinical, Journal, CINV:  Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. (Pubmed Central) -  Aug 21, 2021   
    P3
    To evaluate whether adding aprepitant to palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimens among women with gastrointestinal cancer at higher risk...Patients were randomly assigned to the aprepitant group (aprepitant, 125 mg, orally 60 minutes before initiation of chemotherapy on day 1 and 80 mg orally each morning of days 2 and 3; palonosetron, 0.25 mg, intravenously; and dexamethasone, 6 mg, orally 30 minutes before chemotherapy initiation on day 1) or the placebo group (placebo, 125 mg, orally 60 minutes before initiation of chemotherapy on day 1 and 80 mg orally on each morning of days 2 and 3; palonosetron, 0.25 mg, intravenously; and dexamethasone, 12 mg, orally 30 minutes before chemotherapy initiation on day 1)...The combination of aprepitant with palonosetron and dexamethasone provided increased antiemetic efficacy in the FOLFOX or FOLFIRI chemotherapy regimen and was well tolerated by younger women with gastrointestinal cancer who have a history of little or no alcohol consumption. ClinicalTrials.gov Identifier: NCT03674294.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    [VIRTUAL] Colorectal Cancer () -  Aug 19, 2021 - Abstract #APDW2021APDW_655;    
    Immune checkpoint inhibitors are now an established treatment of MMR deficient (MMRd) colorectal cancer and compelling clinical signal is also seen in MMR proficient (MMRp) patients with combination immune checkpoint inhibition. The current landscape of systemic therapy for colorectal cancer has impactfully improved survival outcomes for patients especially over the last 20 years.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
    Trial completion date, Trial primary completion date, Metastases:  Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT) (clinicaltrials.gov) -  Aug 19, 2021   
    P2,  N=30, Recruiting, 
    These promising findings warrant further evaluation in a larger trial. Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
  • ||||||||||  oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
    Enrollment closed, Enrollment change, Combination therapy, Metastases:  D6070C00005: MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. (clinicaltrials.gov) -  Aug 19, 2021   
    P1b/2,  N=208, Active, not recruiting, 
    Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021 Recruiting --> Active, not recruiting | N=339 --> 208
  • ||||||||||  Trial completion date, Trial primary completion date:  A Study in Adults With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Aug 18, 2021   
    P2,  N=100, Active, not recruiting, 
    The overall survival time from the beginning of first-line chemotherapy was 69.4 months. Trial completion date: Jan 2022 --> Jul 2022 | Trial primary completion date: Jul 2021 --> Jan 2022
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
    Enrollment change, Trial suspension:  SULTAN: Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (clinicaltrials.gov) -  Aug 18, 2021   
    P2,  N=20, Suspended, 
    Trial completion date: Sep 2021 --> Sep 2027 | Trial primary completion date: Sep 2021 --> Sep 2024 N=140 --> 20 | Recruiting --> Suspended
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  Predicting the Response to FOLFOX-Based Chemotherapy Regimen from Untreated Liver Metastases on Baseline CT: a Deep Neural Network Approach. (Pubmed Central) -  Aug 18, 2021   
    In this paper, we propose a fully automated framework based on deep convolutional neural networks (DCNN) which first differentiates treated and untreated lesions to identify new lesions appearing on CT scans, followed by a fully connected neural networks to predict from untreated lesions in pre-treatment computed tomography (CT) for patients with CLM undergoing chemotherapy, their response to a FOLFOX with Bevacizumab regimen as first-line of treatment...Our DCNN approach trained on 444 lesions from 202 patients achieved accuracies of 91% for differentiating treated and untreated lesions, and 78% for predicting the response to FOLFOX-based chemotherapy regimen. Experimental results showed that our method outperformed traditional machine learning algorithms and may allow for the early detection of non-responsive patients.